Severity
Moderate
FDA Drug recall · Reported November 2, 2022
Subpotent Drug: Out of specification for assay
AuroMedics Pharma LLC recalled Fondaparinux Sodium Injection, USP, 7.5 mg per 0.6 mL, Single Dose, Prefilled Syringe, Di… - a moderate-severity action.
Fondaparinux Sodium Injection, USP, 7.5 mg per 0.6 mL, Single Dose, Prefilled Syringe, Di… was recalled by AuroMedics Pharma LLC in November 2, 2022. Reason: Subpotent Drug: Out of specification for assay. Check the official notice for the remedy. Verify recall #D-0020-2023 with the FDA Drug before acting.
The recall
AuroMedics Pharma LLC issued this moderate-severity FDA Drug recall-Subpotent Drug: Out of specification for assay.
Sourced from official FDA Drug enforcement records. Verify recall #D-0020-2023 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0020-2023) was formally reported on November 2, 2022, with the manufacturer initiating the action on September 30, 2022. It is classified under Moderate severity (Class II), with a current status of Terminated. AuroMedics Pharma LLC is listed as the recalling firm, operating out of East Windsor, NJ. Federal records list the affected scope as 11,520 units.
The documented reason for this recall is: Subpotent Drug: Out of specification for assay Distribution data in the federal record shows the product reached: Nationwide in the USA. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
11,520 units
Related Recalls
6
5 from same agency
Fondaparinux Sodium Injection, USP, 7.5 mg per 0.6 mL, Single Dose, Prefilled Syringe, Distributed by: AuroMedics Pharma LLC 279 Princeton-Hightstown Rd. E. Windsor, NJ 08520. Made in India. NDC 55150-232-10 (carton)NDC 55150-232-00 (syringe)
Subpotent Drug: Out of specification for assay
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Terminated |
| Recall number | D-0020-2023 |
| Date reported | November 2, 2022 |
| Date initiated | September 30, 2022 |
| Recalling firm | AuroMedics Pharma LLC |
| Firm location | East Windsor, NJ |
| Affected scope | 11,520 units |
| Distribution | Nationwide in the USA |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported November 2, 2022. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.